Who founded Brink Therapeutics?

Brink Therapeutics was founded by Jonathan Naccache in 2024.

Who are Brink Therapeutics's investors?

Brink Therapeutics's investors include Kima Ventures, Breega, Kurma Partners.

Where is Brink Therapeutics headquartered?

Brink Therapeutics is headquartered in Paris, FR.

Brink Therapeutics

Paris, FR · Founded 2024 · 11 employees on LinkedIn · 3 known investors

Find your way into Brink Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

229 people can intro you to Jonathan

Ask Hugo Barra to introduce you to Jonathan Naccache

You →Hugo · together at Detect →Jonathan

Your email: who you already know at Brink Therapeutics, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Brink Therapeutics team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Brink Therapeutics is a TechBio company developing programmable integrases, a nuclease-free platform for precise, large-payload genomic insertion of therapeutic genes for cell and gene therapy. It combines directed evolution, metagenomics, and generative AI to engineer insertion enzymes for applications such as CAR-T manufacturing and correcting monogenic diseases, and works with pharma and biotech partners on licensing and co-development.

AI & Machine Learning Biotech Deep Tech

Founders & leadership

Brink Therapeutics was founded in 2024 by Jonathan Naccache.

Jonathan Naccache Co-founder (Directeur de la publication)Jonathan Naccache holds a Ph.D. from ESPCI (PSL) and an MBA from INSEAD Business School, and is co-founder of Brink Therapeutics, a company developing programmable integrases for genomic insertion in cell and gene therapy applications.

HarryFounder

Andrew

Investors · 3

Kima Ventures✓ confirmed by Brink TherapeuticsParis · $50K – $5M

How we know: Kima Ventures's portfolio page · the company's own site · Not right? Tell us

Breega✓ confirmed by Brink TherapeuticsLondon · $540K – $16.2M

How we know: the company's own site · a partner's Signal profile · Not right? Tell us

Kurma Partners✓ confirmed by Brink TherapeuticsParis · $162K – $10.8M

How we know: the company's own site · a partner's Signal profile · Not right? Tell us

Related companies · 5

StingraytxStingray is an oncology-focused biotech company developing drugs from discovery through clinical development to commercialization, led by scientists and physicians with experience in building oncology companies.

virionVirion Therapeutics develops CD8+ T cell-based immunotherapies using genetically encoded checkpoint modifiers delivered with target-specific antigens via a viral vector platform, targeting cancers and chronic infectious diseases. Its lead product, VRON-0200, is in clinical development as a potential functional cure for chronic hepatitis B.

RelayRelay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques. The platform serves pharmaceutical and biotech researchers seeking to accelerate drug discovery across multiple phases of development.

Remix TherapeuticsRemix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders. The company applies precision medicine approaches across oncology and other therapeutic areas.

Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.

Companies working in the same space as Brink Therapeutics.

Frequently asked questions

What does Brink Therapeutics do?: Brink Therapeutics is a TechBio company developing programmable integrases, a nuclease-free platform for precise, large-payload genomic insertion of therapeutic genes for cell and gene therapy. It combines directed evolution, metagenomics, and generative AI to engineer insertion enzymes for applications such as CAR-T manufacturing and correcting monogenic diseases, and works with pharma and biotech partners on licensing and co-development.
Who founded Brink Therapeutics?: Brink Therapeutics was founded by Jonathan Naccache in 2024.
Who are Brink Therapeutics's investors?: Brink Therapeutics's investors include Kima Ventures, Breega, Kurma Partners.
Where is Brink Therapeutics headquartered?: Brink Therapeutics is headquartered in Paris, FR.